Brief: 4D Molecular Therapeutics Q3 Net Income USD -43.843 Million Vs. IBES Estimate USD -38.4 Million
13/11/2024 21:05
Nov 13 (Reuters) - 4D Molecular Therapeutics Q3 revenue USD 3 thousand vs. IBES estimate USD 558.3 thousand. * Q3 operating income USD -51.132 million vs. IBES estimate USD -43.2 million * Q3 basic EPS USD -0.79 * Q3 operating expenses USD 51.135 million
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings